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Objectives:  Age-related  macular  degeneration  (AMD)  is  the  commonest  cause  of blindness  in  West-
ern  populations.  Risk  is inﬂuenced  by  age,  genetic  and  environmental  factors.  Complement  activation
appears  to  be  important  in the  pathogenesis  and  associations  have been  found  between  AMD  and  genetic
variations  in  complement  regulators  such  as  complement  factor  H.  We  therefore  investigated  other
complement  regulators  for association  with  AMD.
Methods:  We  carried  out  a case–control  study  to  test  for  association  between  AMD  and  single  nucleotide
polymorphisms  (SNPs)  spanning  the  genes  encoding  complement  factor  P (CFP, properdin),  CD46  (mem-
brane  cofactor  protein,  MCP),  CD55  (decay  accelerating  factor,  DAF)  and CD59  (protectin).  All  cases  and
controls were  examined  by  an  ophthalmologist  and  had independent  grading  of  fundus  photographs  to
conﬁrm  their  disease  status.
Results:  20  SNPs  were  genotyped  in  446  cases  and  262  controls.  For  two  SNPs  with  p-values  approaching
signiﬁcance  additional  subjects  were  genotyped  to increase  the  numbers  to  622  cases  and  359  controls.
There  was  no  evidence  of  association  between  AMD  and  any  of  the  SNPs  typed  in  CFP,  CD46,  CD55  or
CD59.
Conclusions:  In a case–control  sample  that  has  shown  the  well  established  associations  between  AMD  and
variants  in CFH,  CFB  and  C3  there  was  absence  of  association  with  SNPs  in  CFP,  CD46,  CD55  and  CD59.
This  suggests  that  these  are  not  important  susceptibility  genes  for AMD.
© 2011 Elsevier GmbH. All rights reserved.
Introduction
Age-related macular degeneration (AMD) is a major cause
of visual impairment in people over 50 years of age and the
commonest cause of blindness in Western populations (Jager
et al. 2008). It affects the macula, the region of the retina rich in
Abbreviations: AMD, age-related macular degeneration; ARM, age-related mac-
ulopathy; CFB, complement factor B; CFH, complement factor H; CI, conﬁdence
interval; CPI, complement factor I; CFP, complement factor P; CNV, choroidal neo-
vascularisation; DAF, decay accelerating factor; DNA, deoxyribonucleic acid; GA,
geographic atrophy; HWE, Hardy–Weinberg equilibrium; MAC, membrane attack
complex; MAF, minor allele frequency; MCP, membrane cofactor protein; OR, odds
ratio; RPE, retinal pigment epithelium; SNP, single nucleotide polymorphism.
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photoreceptors which provides detailed central vision. In the early
stages of the disease (age-related maculopathy, ARM), deposits
called drusen form between the retinal pigment epithelium (RPE)
and underlying choroid. Later in the disease there is atrophy of
the RPE and overlying photoreceptor cells (geographic atrophy,
GA) and/or aberrant choroidal neovascularisation (CNV, also called
wet  AMD) (Jager et al. 2008). Susceptibility to AMD  is inﬂuenced
by age, ethnic background, genetic and environmental factors,
particularly smoking (Jager et al. 2008; Swaroop et al. 2009).
Common variants in a number of genes have been shown to
inﬂuence the risk of developing AMD  (Swaroop et al. 2009), includ-
ing complement factor H (CFH) (Klein et al. 2005; Haines et al.
2005; Edwards et al. 2005; Hughes et al. 2006), complement factor
B (CFB) and/or complement 2 (C2) (Gold et al. 2006), complement
3 (C3) (Yates et al. 2007) and complement factor I (CFI) (Fagerness
et al. 2009). The involvement of genes in the complement pathway,
particularly complement regulators, together with the ﬁnding
that drusen contain proteins associated with inﬂammation and
0171-2985/$ – see front matter ©  2011 Elsevier GmbH. All rights reserved.
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Table 1
Disease status, sex, age and smoking history of subjects.a
Core sample Enlarged sample
Controls Cases Controls Cases
Number of subjects 262 446 359 622
Disease  status
Age-related maculopathy (ARM) 19 26
Geographic atrophy (GA) 88 126
Choroidal neovascularisation (CNV) 267 373
Both  GA and CNV 72 97
Sex
Male  105 (40%) 207 (46%) 146 (41%) 283 (46%)
Female 157 (60%) 239 (54%) 213 (59%) 339 (54%)
Age
Mean  age, years (SD) 75.7 (7.8) 80.4 (6.8) 75.1 (7.9) 79.4 (7.1)
Pack  years of cigarette smokingb
0 106 (41%) 169 (38%) 150 (42%) 230 (37%)
0.1–20  103 (39%) 127 (29%) 133 (37%) 175 (28%)
20.1–40 39 (15%) 99 (22%) 56 (15%) 137 (22%)
>40  14 (5%) 51 (11%) 20 (6%) 79 (13%)
a Signiﬁcant differences (at p-value ≤ 0.05) between cases and controls are reported in bold.
b Information on smoking was missing for 1 case in the enlarged sample.
immune-mediated processes (Mullins et al. 2000; Anderson et al.
2010) supports the hypothesis that complement activation is
important in the pathogenesis of AMD. We  have investigated
variants in the major genes encoding proteins in the alternative
complement pathway for evidence of association with AMD
and the results for CFH, CFB, CFI, C3 and C5 have been reported
elsewhere (Sepp et al. 2006; Yates et al. 2007; Cipriani et al. 2011).
Because complement activation appears to be central to the patho-
genesis of AMD, we have studied other regulators of the alternative
complement pathway and the results are presented here.
Materials and methods
Patients and controls
The sample comprised cases with predominantly advanced
AMD  (GA or CNV) and spouse controls recruited from hospital oph-
thalmic clinics in London and the South East of England. All subjects
described themselves as “white” on a recruitment questionnaire.
The study had Research Ethics Committee approval and written
consent was obtained from all participants. Subjects were exam-
ined by an ophthalmologist and health, lifestyle and smoking data
were collected. All subjects had colour, stereoscopic fundus pho-
tography of the macular region. These images were independently
graded at the Reading Centre, Moorﬁelds Eye Hospital, London
using the International Classiﬁcation of Age-related Maculopathy
and Macular Degeneration (Bird et al. 1995).
SNP selection and genotyping
Genomic DNA was extracted from peripheral blood leucocytes
and typed for variants spanning the genes encoding comple-
ment factor P (CFP, properdin), CD46 (membrane cofactor protein,
MCP), CD55 (decay accelerating factor, DAF) and CD59 (protectin).
SNPs were selected from the International HapMap Project (The
International HapMap Consortium 2003) database (release 19) for
the CEPH population (Utah residents with ancestry from northern
and western Europe). In an initial round of genotyping, SNPs with
a minor allele frequency of at least 10% were selected to cover the
main blocks of linkage disequilibrium. Subsequently, genetic cov-
erage of the four genes of interest was formally calculated using the
Tagger tag SNP selection algorithm (de Bakker et al. 2005) imple-
mented in Haploview v4.1 (Barrett et al. 2006) and reported as
percentage number of CEPH HapMap SNPs (genotype rate ≥ 90%;
minor allele frequency (MAF) ≥ 1%; Hardy–Weinberg equilibrium
(HWE) p-value ≥ 10−4; maximum number of Mendelian errors = 1)
captured by (at least) one genotyped SNP (at r2 ≥ 0.80). On the
basis of this analysis, additional genotyping was carried out and
the ﬁnal coverage achieved was 83% for CFP, 71% for CD46, 92% for
CD55 and 71% for CD59. SNPs were genotyped using the ABI PRISM
SNaPshot ddNTP Primer Extension Kit and a 3100 Genetic Analyser
(Applied Biosystems) with the exception of rs7060246 which was
typed using Taqman (Applied Biosystems). Manufacturers’ proto-
cols were followed.
Statistical analysis
Differences in the demographic characteristics of cases and con-
trols were assessed using the Fisher’s Exact test for categorical
variables and the two sample Mann–Whitney test for continuous
variables as implemented in STATA (Version 11.1, StataCorp LP,
College Station, TX). A difference was  considered signiﬁcant if the
p-value was found to be less than 0.05. Genetic association analysis
was  conducted using PLINK v1.07 (Purcell et al. 2007). Departure
from HWE  was assessed in controls. SNP association analysis was
performed using the Cochran–Armitage trend test and correspond-
ing p-values are reported. Odds ratios (ORs) were calculated using
referent minor allele and are presented with 95% conﬁdence inter-
vals (CIs). We  performed logistic regression analyses adjusting for
age and pack years of cigarette smoking to address the possibil-
ity that SNP genotypes were confounded by these demographic
factors.
Results
20 SNPs spanning the four genes of interest were genotyped in
446 cases and 262 controls. For two SNPs with p-values approach-
ing statistical signiﬁcance, additional subjects were genotyped to
increase the numbers to 622 cases and 359 controls. Data on dis-
ease status, sex, age and smoking history of subjects are given in
Table 1. The SNPs that were typed in each gene are listed in Table 2
together with the results of genotyping and tests for association.
For all SNPs no departure from HWE  was  observed in control sam-
ples. There was  no evidence of association between AMD  and any
of the SNPs in CFP, CD46, CD55 and CD59. Adjusting the analysis
for age and pack years of cigarette smoking, excluding cases with
ARM or conﬁning the analysis to cases with either CNV or GA did
not signiﬁcantly alter the estimates (results not shown).
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Table  2
Association results for the 20 SNPs in the four complement regulator genes.
Gene SNP Minor
allele (a)
Major
allele (A)
Genotype countsa
(aa/Aa/AA)
Minor allele frequency OR 95% CI p-valueb
Cases Controls Cases Controls
CFP rs909523 T G 18/89/129 13/58/81 0.27 0.25 1.1 0.8–1.4 0.73
rs7060246 T C 1/30/204 1/19/137 0.08 0.07 1.1 0.7–1.8 0.95
CD46  (MCP) rs2796267 G A 97/205/144 43/139/80 0.45 0.43 1.1 0.9–1.3 0.52
rs2724385 T A 99/224/115 63/120/74 0.48 0.48 1.0 0.8–1.3 0.91
rs2796269 T C 55/188/200 32/109/119 0.34 0.33 1.0 0.8–1.3 0.89
rs2724374 C A 15/166/259 12/104/145 0.22 0.25 0.9 0.7–1.1 0.31
rs3109808 C A 70/231/142 48/127/84 0.42 0.43 1.0 0.8–1.2 0.66
rs6657476 T G 15/166/263 12/105/143 0.22 0.25 0.9 0.7–1.1 0.22
rs7144 G A 69/230/144 46/132/83 0.42 0.43 0.9 0.8–1.2 0.60
CD55  (DAF) rs4844591 G A 55/178/195 25/112/120 0.34 0.32 1.1 0.9–1.4 0.43
rs7544288 A G 104/272/243 66/168/124 0.39 0.42 0.9 0.7–1.1 0.19
CD59 rs1047581 C T 39/189/203 28/94/121 0.31 0.31 1.0 0.8–1.3 0.97
rs7046  A G 61/195/161 37/103/110 0.38 0.35 1.1 0.9–1.4 0.35
rs17760306 G T 14/105/307 8/67/174 0.16 0.17 0.9 0.7–1.2 0.62
rs831631 C G 66/210/163 39/102/114 0.39 0.35 1.2 0.9–1.5 0.18
rs12272807 T C 2/72/371 2/52/205 0.09 0.11 0.8 0.5–1.1 0.15
rs1738548 C T 47/179/203 28/100/123 0.32 0.31 1.0 0.8–1.3 0.78
rs2231454 A G 3/88/528 5/59/294 0.08 0.10 0.8 0.6–1.1 0.12
rs3181274 A G 61/193/175 37/106/107 0.37 0.36 1.0 0.8–1.3 0.80
rs17760694 C T 16/131/291 14/83/163 0.19 0.21 0.8 0.6–1.1 0.22
a SNPs were genotyped in 446 cases and 262 controls. rs7544288 and rs2231454 were typed in the enlarged sample of 622 cases and 359 controls.
b p-value for the Cochran–Armitage trend test.
Discussion
The complement system mediates host defence against
pathogens, the elimination of immune complexes and apoptotic
cells, and it facilitates adaptive immune responses (Walport 2001).
There is good evidence that complement activation is important in
the pathogenesis of AMD  (see accompanying review, Khandhadia
et al. 2012). Drusen, the hallmark lesion of early AMD, contain
proteins from the alternative complement pathway including CFH,
C3 and its activation products, and terminal pathway components
including C5 and the membrane attack complex (MAC) (Mullins
et al. 2000; Anderson et al. 2010). Patients with AMD  have ele-
vated levels of complement activation products in their circulation
(Scholl et al. 2008; Reynolds et al. 2009; Hecker et al.2010).
Complement activation is controlled by a large number of sol-
uble and membrane bound regulatory proteins (Zipfel and Skerka
2009). CFH is the most important ﬂuid phase regulator, present at
high concentration in the plasma and body ﬂuids and a key regu-
lator of the alternative complement pathway. There is conclusive
evidence that the common expressed variant Y402H (rs1061170)
in the CFH gene inﬂuences susceptibility to AMD  (Klein et al. 2005;
Haines et al. 2005; Edwards et al. 2005) with heterozygotes and
homozygotes for the 402H allele being 2.5 and 6 times more likely
to have AMD  respectively (Thakkinstian et al. 2006). Other CFH
variants are independently associated with AMD  (Li et al. 2006).
A deletion of the neighbouring CFHR3 and CFHR1 genes has been
shown to be protective for AMD  (Hughes et al. 2006) and these
proteins are also involved in complement regulation. CFI is a cofac-
tor with CFH for the inactivation of C3b and SNPs at the CFI locus
also show an association with AMD  (Fagerness et al. 2009). In
the present study, we investigated the ﬂuid phase protein, com-
plement factor P (properdin). CFP is a stabilising component of
the alternative pathway convertases and can bind to cells and
pathogens, promoting convertase assembly and targeted phago-
cytosis (Kemper and Hourcade 2008). We  found no evidence of an
association between the SNPs typed in CFP and AMD. A recently
published study of genetic variants in CFP from Finland was also
negative (Seitsonen et al. 2010).
Cell surfaces are also protected from complement activation
by membrane bound proteins and we have investigated SNPs
in the genes encoding three of these for association with AMD:
CD46 (membrane cofactor protein, MCP), CD55 (decay accelerat-
ing factor, DAF) and CD59 (protectin). CD46 acts as cofactor for
CFI mediated cleavage of C3b (Kim and Song 2006). CD55 inhibits
the formation and accelerates the decay of C3 and C5 convertases
(Kim and Song 2006). CD59 prevents ﬁnal assembly of the MAC
(Kimberley et al. 2007). We found no evidence of association with
the SNPs typed in any of these genes. However, based on the conﬁ-
dence intervals for our odds ratios there is still the possibility that
an association might exist up to a maximum OR of 1.8 in the case of
rs7060246, and more generally in a range between 0.5 and 1.5 for
other SNPs. Moreover, we  cannot exclude the possibility of asso-
ciation with a common variant in poor LD with the SNPs typed, or
indeed a rare variant that inﬂuences susceptibility to AMD.
We have studied these four complement pathway genes in
a large well phenotyped case–control sample. The subjects used
in the study were all examined by an ophthalmologist and had
independent grading of their fundus photographs to conﬁrm their
disease status. This same sample has been used in other studies of
AMD  susceptibility and shows the expected associations with CFH,
CFB/C2 and C3 (Sepp et al. 2006; Yates et al. 2007). The absence of
association with SNPs in CFP, CD46, CD55 and CD59 suggests that
these are not important susceptibility genes for AMD.
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